POST 7th_NIF
> ATTENDEES
​> INVESTORS
> PRESENTERS
> SPONSORS
> SUPPORTERS

20-MINUTE PRESENTERs

​Actinogen Medical Ltd.
[ASX: ACW]

Actinogen is a Phase 2 clinical-stage biopharmaceutical company developing a once-a-day oral small molecule to treat Alzheimer's Disease and cognitive impairment associated with depression. Its lead molecule Xanamem works by a unique non-amyloid non-tau mechanism to reduce tissue levels of the "stress hormone" cortisol in the brain without altering plasma cortisol.​

https://actinogen.com.au/

​AlgoTx

AlgoTx develops innovative solutions for complex pain. 

The ongoing Phase 2 ACT trial (US EU) assesses the efficacy of ATX01 in Chemotherapy-Induced Peripheral Neuropathy (FDA Fast-Track), whilst the Phase 2 EASE trial (US EU) focuses on the orphan disease Erythromelalgia (US & EU ODD, FDA Fast-Track.

https://algotx.com/

Cognition Therapeutics, Inc.
[​NASDAQ: CGTX]

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and geographic atrophy secondary to dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.​

https://cogrx.com/

CuraSen Therapeutics, Inc.

CuraSen was established Oct 2018 with the goal of revitalizing lost adrenergic stimuli to the brains of patients with AD, PD and many other neurodegenerative diseases, whose cognitive capacities and daily activities continue to deteriorate without restorative, life-improving therapeutic options.  This sadly remains evident in most patients with neurodegenerative disease despite recent approval milestones in AD.

CuraSen’s candidates rapidly improve cognition, memory, attentiveness and emotional strength, all via action on a clinically proven medicinal pathway.  Our unique combination drug approach allows safe, well-tolerated and brain-selective activation of adrenoceptors - normally essential for maintenance of cognition and mood - whose stimulation diminishes in the earliest prodromal periods of degeneration due to decline in integrity of the pontine locus coeruleus, source of the limbic and cortical norepinephrine (noradrenaline).

CuraSen has recently achieved clinical proof of concept for two combinations therapeutic, CuraCN & CuraXN, in AD and PD patient studies, within a treatment period as short as 2-weeks.  Longer term durability and dose ranging studies are planned, which will enable fuller elaboration of the breadth and magnitude of clinical improvement, as well as impact un underlying pathological hallmarks.

https://curasen.com/

Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease – Galimedix’s initial areas of focus. The Company’s approach targets toxic Aβ oligomers and protofibrils.  Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer’s disease. Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned for GAL-101 and for GAL-201, Galimedix oral drug for Alzheimer´s disease.​

galimedix.com/

HanAll Biopharma
[​XKRX: 009420]

Founded in 1973, HanAll Biopharma has been at the forefront of scientific innovation, consistently striving to evolve and adapt for the benefit of patients. Our company has actively engaged in collaborations with diverse multinational companies, working together to provide patients with high-value medicines.

In 2007, HanAll embarked on a new venture into the field of biopharmaceuticals. By establishing research and development centers in the United States, we successfully positioned ourselves to enter the global market. This strategic move underscored our commitment to expanding our reach and contributing to the global healthcare landscape. Subsequently, Hanall extended our presence to include Japan and Indonesia.

HanAll's unwavering dedication to improving patient outcomes remains steadfast. We relentlessly explore uncharted territories in the pursuit of treatment options for individuals afflicted by rare and intractable diseases.

Hanall is at the forefront of revolutionizing lives through an exceptional range of pharmaceutical products. Our extensive expertise encompasses various fields such as endocrine, circulatory, and urologic diseases. By demonstrating a profound understanding of immunology, we have propelled ourselves into new territories, broadening our focus to include immunology, oncology, neurology and ophthalmology.

We strive to deliver first-in-class and best-in-class therapeutics to meet the unmet medical needs of patients through the advancement of science. We pursue innovation through strong ethical considerations and a performance, collaborative-oriented culture. Our successful development of multiple therapeutics from discovery through submission is driven by investing in strong protein development resources. In accordance with our vision, we have committed to our innovation, successful partnerships, and investments in the artificial intelligence (AI) space.

http://hanall.com/

​IAMA Therapeutics S.r.l.

IAMA Therapeutics pushes the boundaries of neuroscience drug discovery to develop new therapeutic opportunities and make a difference in children affected by epilepsy, neurodevelopmental and cognitive disorders. IAMA Therapeutics is developing IAMA-6 for potentially treating drug-resistant epilepsies and rare syndromic forms of autism, in addition to chloride modulators targeting neuropsychiatric conditions characterized by cognitive impairment.​

https://iamatherapeutics.com/

Minoryx Therapeutics S.L.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million.​

https://minoryx.com/

Oryzon Genomics, S.A.
[​BME: ORY]

A public clinical-stage biopharma developing epigenetics for CNS disorders and Oncology. +50 highly qualified professionals located in Barcelona, Boston, and San Diego. Listed in Spain, aiming at NASDAQ listing. With two uncorrelated Phase II compounds: vafidemstat in CNS, and iadademstat in oncology against LSD1, a Histone demethylase.

Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor that has been administered to +430 patients. With positive results reducing aggression in a Phase IIa basket trial in psychiatric patients, now the company has finalized the recruitment in its Phase IIB called PORTICO (210 patients) aiming to show a general improvement of the disease and a reduction in aggressivity. The company expects to provide Topline Data in 1Q24.

Additionally, the company is running another Phase II in schizophrenia patients aiming to show an improvement in the negative symptoms and in the cognitive impairment-associated symptoms.

Also launching a CNS personalized medicine program, starting with  a Phase I/II trial in Kabuki syndrome expected to start in 2024.

https://oryzon.com/

Quince Therapeutics
[​NASDAQ: QNCX]

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn and X.

https://quincetx.com/

STALICLA SA

STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.

STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.

STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value.

Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb.

​STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.

https://stalicla.com/

Synendos Therapeutics AG

Synendos is a new, dynamic neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and other CNS disorders.

We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos’ lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first in class, new chemical entities that modulate the ECS through a self-limiting mode of action with the potential to deliver meaningful benefits to patients.

Synendos' current focus is on anxiety and mood-related diseases characterized by an endocannabinoid deficiency and with high unmet medical need such as post-traumatic stress disorder (PTSD). We have submitted our CTA and anticipate that SYT-510 will enter clinical studies in late 2023 and Synendos will transition to a clinical stage biotech.

Synendos closed a Series A round of CHF 24m in April 2021 with a strong syndicate of investors including Kurma Partners, Sunstone Life Science Ventures, Ysios Capital and Bernina BioInvest. In addition, Synendos has raised CHF 4m in grant funding from a variety of accelerators, foundations and EU funding schemes. These have provided a firm validation of the technology, approach and potential success of the company.

All the assets and targets relevant to the company are protected by a robust series of patents, filed or granted in all major markets.

https://synendos.com/

Theranexus SA
[EPA: ALTHX]

Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease.​

https://theranexus.com/

Tonix Pharmaceuticals Holding Corp.
[NASDAQ: TNXP]

At Tonix, we are focused on identifying and developing candidates that have the promise to treat and prevent human disease and alleviate suffering. Through our own development, in-licensing, collaborations and acquisitions we are curating an innovative and effective portfolio that targets the relief of pain and attenuates infection. Currently, our pipeline is primarily comprised of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our infectious disease portfolio includes an innovative live virus vaccine platform. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio.​

https://tonixpharma.com/

10-MINUTE PRESENTERS

Acasti Pharma Inc.
[​NASDAQ: ACST]

Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Acasti's lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical asset, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.​

www.acasti.com/en

Acelot, Inc.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson’s, diabetes and cancer. Acelot’s platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases.  We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS.  Our platform was invested by UCSB Computer Science Professor Dr. Ambuj Singh. 

Acelot’s first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024 with plans to begin Phase I in-human studies for ALS in late 2025. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer’s.  ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a discovery pipeline with hits displaying potent in vitro properties for alpha synuclein and tau. Acelot is raising funds for ACE-2223’s first in-human studies along with progressing its discovery pipeline.

https://acelot.com/

AgenT S.A.S.

AgenT is a French life sciences company on a mission to defeat Alzheimer’s by targeting the silent phase.

By combining multi-omics assays with advanced machine learning techniques, we found new blood biomarkers (not abeta or tau) deregulated from the earliest stages of the disease. Using this proprietary database, we are developing an accurate blood diagnosis and the next generation of precision therapies to treat Alzheimer’s.

Our two blood tests, B-HEALED™ and B-AHEAD™, have been validated in a clinical validation involving 632 participants sampled up to 18 years prior to the dementia onset and coming from the US, Europe and Australia.

We are pioneering a new method for detecting and treating Alzheimer's disease in its silent stage to prevent the onset of irreversible symptoms.

https://agent-biotech.com/

bloom science

Bloom Science is a clinical-stage, central nervous system (CNS) company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx™ drives AI-assisted discovery of unique metabolites/bioactive compounds, pathways and microbial strains from clinical responder data. This enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles.

The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics targeting neuronal oxidative stress, neuroinflammation, metabolic energetics and hyperexcitation.

Bloom Science is advancing a deep pipeline of programs in rare epilepsies and neurodegenerative and cognitive disorders. Our lead program, BL-001 is heading into Phase 2 study in Dravet syndrome, and a Phase1b study in Amyotrophic Lateral Sclerosis (ALS).

bloomscience.com/

GeNeuro SA
[​EPA: GNRO]

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Post-COVID (PASC) and Amyotrophic Lateral Sclerosis (ALS).

https://geneuro.com/

GliaPharm SA

GliaPharm's pioneering approach is to stimulate energy utilization in the brain by targeting a type of glial cells called astrocytes, representing an innovative approach for the treatment of neurological and psychiatric disorders.
​
https://gliapharm.com/

Kynexis Therapeutics

Kynexis is a new biotech company, backed by Forbion and Ysios. It is taking a novel approach to cognitive impairment associated with schizophrenia (CIAS)

Cognitive impairment is a major cause of disability in a large majority of people with schizophrenia, and currently there are no approved drugs for CIAS. Dysregulation of the kynurenine pathway is hypothesized to cause schizophrenia, and we are taking a human biology-based, first-in-class approach to target CIAS with our lead molecule, KYN-5356.

For decades, research on novel potential therapies for neuropsychiatric disorders relied primarily on animal models. At Kynexis, we use a human biology-based approach for our target rationale, a causal biomarker approach to assert our mechanism of action in clinical development, and a human genetics approach to identify responder sub-populations. We believe that this convergence of human data for rationale, biomarkers and genetics uniquely positions this program for success in CIAS and possibly additional indications as well.

www.kynexistx.com/

​Lys Therapeutics

First-in-class biotherapies against neurological diseases.

Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat unmet medical needs in patients suffering from neurovascular or neurodegenerative disorders by targeting blood-brain barrier (BBB) dysfunction.

Targeting neuroinflammation to tackle neurodegeneration.

https://lystherapeutics.com/

Neuro-Innovators, LLC

Neuro-Innovators, LLC (NIV) is a clinical stage drug company engaged in the commercialization of compound drugs that increase neuroplasticity, the brain’s capacity to remodel, rewire, recover.

From its proprietary list of drugs with published neuroplastic properties NIV is designing combinations based on observed mechanisms of neuroplasticity and how each effects a specific condition. Candidate conditions range from: brain injuries, to chronic brain trauma, to neurodegenerative diseases.

Since NIV is using only FDA approved drugs, NIV is able to follow the FDA’s 505(b)(2) and Fast Track processes, resulting in shorter time (3-5 vs. 10+ yrs) and lower cost (~$33M vs. $1+B for New Chemical Entity) to market.

NIV’s first drug, NIV-001, targets patients with chronic motor deficits due to a stroke. This one market segment represents a substantial $20+ billion market. The 7M surviving US stroke patients cost society ~$50B annually, and create significant family, and community burdens. Importantly, this indication is associated with objective, measurable outcome metrics (motor deficits changes). Such clear statistical measures lowers FDA approval risks and clinical trial costs and shortens time to market.

NIV has a letter of intent with a top tier Boston hospital to run its first human clinical study and is driving to close its seed funding of $2.6 M to start the study in Q1 2024. NIV’s Series A & B rounds will total $30M to execute both Phase 2(b) and Phase 3 studies. NIV expects to be an acquisition target in 3 yrs, and commercialize NIV-001 in 5-6 yrs.

https://neuro-innovators.com/

Neuromod Devices

Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. The company specializes in the design and development of bimodal neuromodulation technologies. Neuromod’s Lenire® device was granted FDA de Novo in March 2023 and has been subsequently rolled-out successfully in the US. Real world evidence data from Lenire providers confirm large clinical trial data on the efficacy of Lenire.​

https://neuromoddevices.com/

Newronika S.p.A.

Newronika S.p.A. is a cutting-edge medical device company at the forefront of developing the world's most advanced Deep Brain Stimulation (DBS) system primarily designed for treating Parkinson's disease, tapping into a significant market valued at over $3 billion. The company has successfully pioneered the AlphaDBS system, a closed-loop DBS innovation distinguished by its proprietary control algorithm. This algorithm continually monitors brain signals, dynamically adjusting stimulation parameters to precisely align with each patient's therapeutic requirements.

Beyond Parkinson's disease, Newronika's adaptive DBS system is a versatile platform technology, positioning the company to pursue approvals in diverse indications such as epilepsy, pain, and incontinence. This expansion broadens the total addressable market to well beyond $10 billion.

Newronika has successfully secured funding through a Seed and Series-A round, along with prestigious grants, including a notable €2.5 million EIC grant. Currently, the company is actively raising a Series B round, targeting a substantial $30+ million. With over $10 million already committed to this fundraising effort, the proceeds will be allocated towards supporting the pivotal trial and implementing incremental product improvements, further solidifying Newronika's position as a leader in innovative medical solutions.

https://newronika.com/

Parow Entheobiosciences LLC

Parow Entheobiosciences (ParowBio) aims to develop proprietary, effective and accessible treatments for psychiatric conditions based on entheogenic (traditional psychedelics) molecules through a rigorous, science-based approach from discovery to clinical trials and manufacturing. ParowBio is an opportunity to obtain high potential, low-risk investment exposure to psychedelics biotechnology - offering innovative and effective therapeutics for mental disorders including depression, addiction, PTSD and obsessive-compulsive disorder (OCD). More than 10% of the US population suffers from these conditions and mental illness is among the leading contributors to the global burden of disease.​

​https://parowentheobio.science/

PATH Biotech LLC

PATH BIOTECH LLC is a seed-stageAI-driven precision medicine company in the USA developing novel targets and therapeutics to treat neurological disorders and cancer.  PATH BIOTECH developed a proprietary Precision Medicine Artificial Intelligence Therapeutics (PATH) platform to multi-omics big data from patients for cures of Alzheimer’s, cancer, and aging. We are currently funded by phase-1 NIH STTR grant to fast forward our IP-protected pharmaceutical products towards clinical study in Alzheimer's disease and dementia.Our founders composed a highly inter-disciplinary team, and our expertise range from AI/Machine Learning, biology, pharmacology, to biomedicine chemistry. All founders are tenured faculty at the University of Arizona, USA with decades of research experiences and well-funded federal research grants.

https://pathbiotech.com/

ProNeurogen, Inc.

ProNeurogen is a clinical-stage biotech company developing novel peptide-based therapeutics to treat vascular dementia/mixed dementia and chronic pain.

ProNeurogen therapeutics are also being developed for the treatment of ARIA in AD patients undergoing anti-amyloid antibody therapy.

There are currently no FDA treatments for vascular dementia positioning ProNeurogen to be first-to-market for vascular dementia and mixed dementia.

ProNeurogen’ s lead product, PNA5, will have its FDA IND in Q42023 and is expected to be begin human clinical testing in Q32024.

ProNeurogen has developed a platform of glycosylated-Ang-(1-7) peptides for treatment of memory loss due to chronic inflammation as well as chronic pain. We have advanced and completed pre-clinical testing of our 2 lead compounds, PNA1 and PNA5 to treat dementia.

PNA1 human studies have been used to de-risk the development of our lead candidates and is currently in Phase 2a trials for both vascular cognitive impairment and TBI.

PNA5 has completed IND enabling studies and will begin human clinical trials in Q32024.

Following completion of Phase II studies with PNA5 we will identify a large-pharma partner to complete Phase III trials and take product to market.

https://proneurogen.com/

Psilera Inc.

Psilera is a biopharmaceutical company revolutionizing the development of novel serotonergic drugs which provide rapid therapeutic benefit and fewer side effects than conventional treatments. Their world-class scientific and executive team reimagine psychoactive natural products into effective and insurance-backed take-home therapies for psychiatric, addiction, and neurodegenerative disorders. Their proprietary drug discovery engine, Psilera Third Eye, combines novel syntheses of new compounds with an AI-enabled screening platform to design next-generation neurological drugs at the atomic level.

https://www.psilera.com/

Reunion Neuroscience, Inc.

Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being investigated as a potential treatment for postpartum depression that could provide rapid symptom relief and durable efficacy. RE104 is protected under U.S. Patent No. 11,292,765 issued on April 5, 2022 (priority June 30, 2020), with claims for composition of matter, methods of manufacturing, formulations and methods of use for a genus of hemiester tryptamines, including RE104, which could provide protection out to June 30, 2041.​

https://reunionneuro.com/

Sinaptica Therapeutics, Inc.

Sinaptica Therapeutics is a clinical-stage company that is developing a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease. The company’s SinaptiStim System represents a totally new approach to treating AD by enhancing neuroplasticity via noninvasive neurostimulation of key brain networks involved in memory. The therapy has been clinically demonstrated to slow the progression of cognitive decline and functional decline in patients with mild-to-moderate Alzheimer's disease.​

https://sinapticatx.com/

Tessara Therapeutics Pty Ltd.

Problem: Traditional in vitro and animal models used during drug development misrepresent the physiology of the human brain resulting in extremely high failure rates, exceeding 99.5%, during the development of drugs for neurodegenerative diseases and dementia.

Solution: Tessara's RealBrain® is a pioneering technology platform that produces highly reproducible in vitro 3D models of the human brain, offering transformative drug discovery solutions for companies developing neurological drugs. With physiological accuracy, RealBrain® overcomes the limitations of existing technologies, providing a replicable and easily manufacturable human brain model. RealBrain® is designed to revolutionize neurology drug discovery by enabling efficient testing of new drugs while reducing the need for animal models. Key features include a close representation of human brain physiology, high reproducibility, and a rapid development timeframe of only 3 weeks. Its optical clarity allows continuous observation of drug effects and simplified imaging workflows, delivering unprecedented insights into drug impacts on neural network plasticity. Additionally, the platform integrates cutting-edge AI and imaging technology, providing remarkable data insights. Tessara is currently the sole company commercializing such products.

Game-changing product pipeline:
•Alzheimer’s Disease (ADBrain™ model)
•Glioblastoma (GbmBrain™ model)
•Traumatic Brain Injury (TBIBrain™ model)
•Mature, “healthy” brain (ArtiBrain™ model)
•Developing, “healthy” brain (DevBrain™ model)

Tessara has created the first-ever human 3D neural tissue models that are biologically accurate, can be manufactured in large volumes, with high reproducibility, utilize a simple and quick maturation protocol, and are easily compatible with all standard established industrial assay methods. This combination is unique to Tessara. Tessara’s platform enables the development of effective drugs more quickly and cost-effectively than other competing technologies. The RealBrain® technology is easy for pharmaceutical companies to adopt and has compatibility with existing workflows.

https://tessaratherapeutics.com/

TikoMed AB

TIKOMED is a privately held company focused on development of ILB, a small molecule for neurological conditions, documented to phase 2 in ALS and with a MoA supporting several additional indication.

TIKOMED is planning for IND and a Phase 2b study in ALS.

https://tikomed.com/

Zeto, Inc.

Zeto has made it possible for any health care facility to offer an easy, turnkey EEG solution to their patients. We provide a unique, wireless, FDA cleared, dry EEG headset that can be put on by any medical staff within 5 minutes. Live video and data can be interpreted seamlessly via the cloud, further enabled by AI based seizure detection, live EEG monitoring and interpretation services by board certified neurologists. Most importantly, EEG is a well reimbursed procedure with several well accepted CPT and DRG codes for billing, significantly enabling our adoption in the market.​

https://zeto-inc.com/